TRT Jatenzo denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for trt jatenzo are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Jatenzo as "Not FDA-Approved" — and Why That Can Be Appealed

Jatenzo (testosterone undecanoate) is an FDA-approved oral testosterone replacement therapy (TRT) indicated for adult males with hypogonadism caused by certain medical conditions. A denial citing "not FDA-approved" almost always means one of three things: a coding or billing error that misidentified the product; a plan policy that has not been updated to recognize the oral formulation as a distinct, approved product; or a generic clerical mismatch in how the claim was routed. Because FDA approval is a verifiable, public fact, this denial category is among the most straightforward to overturn with the right documentation.

## Federal Appeal Framework

Under ACA Section 2719, non-grandfathered group and individual health plans must provide internal appeal rights and access to independent external review. ERISA Section 503 imposes a full-and-fair review standard on employer-sponsored plans. You have the right to an internal appeal (typically decided within 60 days for standard requests, 72 hours for urgent/expedited), and if that is denied, to an independent external review — generally you must request external review within approximately four months of the final internal denial. An expedited external review is available when a standard timeline would seriously jeopardize your health.

## What to Gather Before You Appeal

• FDA approval documentation. Print the current FDA drug label from the FDA's Drugs@FDA database showing the approved indication and the product's NDA number. This directly refutes any claim that Jatenzo is not approved.
• Diagnosis confirmation. Labs and clinical notes establishing the underlying hypogonadism diagnosis and its medical cause.
• Prescriber medical-necessity letter. Your physician should explain why Jatenzo (specifically the oral route) is medically appropriate for your case, referencing the FDA-approved indication and the applicable endocrinology society guidelines (e.g., the Endocrine Society clinical practice guideline for male hypogonadism).
• Formulary and plan-document excerpts. Pull Aetna's published drug list and medical policy for testosterone products to confirm whether Jatenzo appears and under what tier or criteria.

## How to Structure the Appeal

Open by citing the FDA approval status directly. Include the NDA number and approval date from the FDA label. Then map each element of Aetna's stated denial reason to a documentary rebuttal:

| Denial claim | Your rebuttal + supporting document | |---|---| | Drug not FDA-approved | FDA label + NDA number (attach) | | Indication mismatch | Diagnosis records + prescriber letter | | Coding/billing error | Confirm NDC on claim matches Jatenzo NDC |

Close by requesting that Aetna apply its own published clinical policy for testosterone replacement and confirm whether any additional criteria (prior authorization, step therapy) actually apply — keeping further appeal grounds open if needed.

## Timeline

File your internal appeal in writing as soon as possible. Track the date you submit and log the case reference number. If you do not receive a decision within the plan's stated timeframe, that is itself a reviewable event. Keep copies of everything.